Stocks · News reference

Anixa Biosciences Receives Patent From South Korea's Ministry Of Intellectual Property For Its Breast Cancer Vaccine Technology

Jun 29, 2026, 12:46 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 21, 2026, 12:47 PMBenzinga Newsdesk
IP Australia Grants Patent To Anixa Biosciences’ Breast Cancer Vaccine Technology, Exclusively Licensed From Cleveland Clinic
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global intellectual
ANIX
BenzingaSep 9, 2026, 9:14 PMBenzinga Newsdesk
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share
ANIX
BenzingaAug 24, 2026, 12:57 PMBenzinga Newsdesk
Anixa Biosciences To Present Data On Its Breast Cancer Vaccine At 2026 Cantor Fitzgerald Global Healthcare Conference
ANIX
BenzingaJul 14, 2026, 12:35 PMBenzinga Newsdesk
Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of
ANIX